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Abstract
The number of people suffering from Alzheimer’s disease (AD) is expected to increase dramatically in the coming years, placing a
huge burden on society. Current treatments for AD leave much to be desired, and numerous research efforts around the globe are
focused on developing improved therapeutics. In addition, current diagnostic tools for AD rely largely on subjective cognitive
assessment rather than on identification of pathophysiological changes associated with disease onset and progression. These facts
have led to numerous efforts to develop chemical probes to detect pathophysiological hallmarks of AD, such as amyloid-β plaques,
for diagnosis and monitoring of therapeutic efficacy. This review provides a survey of chemical probes developed to date for AD
with emphasis on synthetic methodologies and structure–activity relationships with regards to affinity for target and brain kinetics.
Several probes discussed herein show particularly promising results and will be of immense value moving forward in the fight
against AD.
Introduction
Alzheimer’s disease (AD) is a progressive neurodegenerative
disorder of the central nervous system currently affecting
~5.4 million Americans, a number that could increase to
11–16 million by the year 2050. In the United States, AD repre-
sents the 6th leading cause of death. Between 2000 and 2008,
the number of deaths caused by AD increased by 66%, a
dramatic rise, especially when compared to other causes of
death, such as heart disease, stroke, prostate and breast cancer,
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and HIV, which decreased by 3–29% during that time period
[1]. As these numbers indicate, AD represents a significant and
increasing burden on our population, and efforts towards the
development of new and improved diagnostics and therapeutics
for this devastating disease are important research endeavors.
Several pathological hallmarks of AD have been identified, and
they include decreased cholinergic neurons and acetylcholine
(ACh) levels, plaques caused by aggregation of the protein frag-
ment amyloid-β (Aβ), tangles associated with irregular phos-
phorylation of tau protein, inflammation and increased oxida-
tive stress from reactive oxygen species (ROS), as well as
dyshomeostasis and miscompartmentalization of metal ions
such as Cu, Fe, and Zn. Observations of these hallmarks have
led to several hypotheses in attempts to explain the underlying
cause of the disease, which is likely multifactorial. However,
the exact cause of AD still remains unknown.
Postmortem histopathological examination of Aβ plaques is
currently the only way to firmly confirm AD [2]. In view of the
limited accessibility to living brain and other central nervous
system (CNS) tissues, AD is currently diagnosed through
memory tests and/or based on the patients’ history [2]. Obvi-
ously these kinds of diagnostic tools lack absolute sensitivity
and accuracy, especially in the early stages of the disease.
Therefore, as Aβ plaques precede the onset of dementia and
cognitive decline in AD patients, their detection by nuclear
imaging techniques such as positron emission tomography
(PET) or single-photon emission computed tomography
(SPECT) represents the presymptomatic diagnostic tool of
choice for AD [3-5].
The presence of different binding sites in Aβ aggregates led
medicinal chemists to investigate and develop a variety of
chemical scaffolds as Aβ-imaging tracers [6-9]. To provide a
high readable signal-to-background ratio, the ideal Aβ-imaging
probes should have certain brain kinetics: a rapid initial brain
uptake and a fast washout. Early efforts towards developing Aβ
stains focused on dyes such as congo red (1), chrysamine G (2),
pinacyanol (3), and thioflavin-T (4) (Figure 1A). However, the
bulky and ionic natures of these dyes prevented them from
crossing the blood brain barrier (BBB), and consequently, no in
vivo benefits were obtained from these initial investigations
[10,11]. During the past decade, efforts directed at developing
probes that display uptake and retention that differ in healthy
and AD-affected brains resulted in a variety of radiolabeled
molecular probes for in vivo PET/SPECT imaging. The scaf-
folds from which these newer radiolabeled probes are derived
include chalcone (5) and its conformationally restricted
analogues flavone (6) and aurone (7); stilbene (8) and its
analogues diphenyl-1,2,4-oxadiazole (9) and diphenyl-1,3,4-
oxadiazole (10); and thioflavin-T analogues such as benzothia-
zole (11), benzoxazole (12), benzofuran (13), imidazopyridine
(14), and benzimidazole (15); as well as quinoline (16) and
naphthalene (17) derivatives (Figure 1B). In this review, we
provide an overview of these AD radiolabeled early-diagnostic
probes according to their scaffolds, with a special emphasis on
their synthesis as well as their structure–activity and brain-
kinetics relationships. We also provide a brief summary of the
latest developments related to the detection of Aβ plaques by
near-infrared fluorescence (NIRF) imaging.
Review
Radiolabels used in PET/SPECT molecular
probes
Even though they decay rapidly, [11C] (t1/2 = 20 min) and [18F]
(t1/2 = 110 min) are the most commonly used radiolabels in
PET/SPECT molecular probes for in vivo imaging of Aβ
plaques [4]. With a half-life (t1/2) of 6.01 h compatible with the
localization and residence time necessary for imaging, tech-
netium-99m [99mTc] is also a radionuclide of choice that is
easily produced by a 99Mo/99mTc generator [12]. Iodine
isotopes such as [125I] are also employed, although much less
frequently [13]. The general synthetic methods utilized to intro-
duce radiolabels into PET probes are outlined in Scheme 1.
These general strategies will be abbreviated as Gs A–D in all
subsequent schemes in this review.
Chalcone and its conformationally restricted
analogues
Chalcone derivatives
Chalcones and indolochalcones, such as 18a–l, 19a,b, 20a,b,
and 21, have been widely reported as Aβ-imaging tracers
(Scheme 2A). Structure–activity-relationship (SAR) studies on
fluorinated chalcones 18a–l have shown that, in general, chal-
cones with tertiary amines in their structures demonstrate good
affinity for Aβ plaques in in vitro models (Ki = 20–50 nM)
(Table 1) [14]. Dimethylation of the amino group seems to be
crucial for Aβ binding, since analogues with free amino groups
or monomethyl amino groups revealed lower affinity [14]. On
the other hand, pegylation is not that essential for plaque
binding as tertiary amine analogues with different degrees of
pegylation (n = 0–3) all showed similar affinity. In biodistribu-
tion experiments using normal mice, the [18F]-labeled chalcone
19a showed high brain uptake rate and good clearance, whereas
the [11C]-labeled chalcone 19b revealed reasonable brain
uptake rate, but very fast clearance [14]. The [18F]-labeled and
[11C]-labeled chalcones 19a and 19b were synthesized using
similar methods, and a representative synthesis of 19a is shown
(Scheme 2B). Aldol condensation between the appropriate
acetophenone 22 and benzaldehyde 23 afforded the chalcone
backbone, which was subsequently pegylated to give 24 and
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Figure 1: Structures of A. dyes originally used to stain Aβ and B. newer scaffolds explored for the development of radiolabeled Aβ probes.
radiolabeled to give 19a. Compound 19b was generated by
using p-nitrobenzaldehyde instead of the corresponding
dimethylamine 23 used in the preparation of 19a [14]. The
resultant nitrochalcone was then reduced by SnCl2 in EtOH to
yield the free amine, which was monomethylated by controlled
addition of an equimolar amount of MeI. The final [11C]-
labeled compound 19b was produced by reacting [11C]CH3OTf
with the secondary amine precursor.
[Re]- and [99mTc]-labeled chalcone analogues 20a and 20b
were also studied (Scheme 2A) [12]. The [Re]-labeled analogue
20a displayed higher affinity for Aβ plaque than did the corres-
Beilstein J. Org. Chem. 2013, 9, 1012–1044.
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Scheme 1: General synthetic strategies (Gs) used to introduce A. 18F, B. 11C, C. 99mTc/Re, and D. 123I and 125I radiolabels into PET probes. Note:
Gs A–D will be used in all subsequent schemes to describe these general synthetic strategies.
ponding [99mTc]-derived compound 20b. However, 20b
showed better brain pharmacokinetics than 20a, as indicated by
its high brain-uptake rate (1.48% ID/g) and rapid wash out from
the CNS (0.17% ID/g at 60 min). Compounds 20a and 20b
were synthesized by reacting a Boc-protected metal chelator
(Scheme 1C) with 4-O-(bromopropyl)hydroxychalcone 25
(Scheme 2C). After removal of the Boc protecting group, the
final [Re]- and [99mTc]-labeled chalcones 20a and 20b were
obtained by treatment with (PPh3)2ReOCl3 and 99mTcGH, res-
pectively [12].
Finally, the radioiodinated indolochalcone 21, among a series of
other derivatives, was prepared through condensation of
4-iodoacetophenone (26) and indole-5-carboxaldehyde (27) to
give 28, which was radiolabeled to give the target compound
(Scheme 2D) [15]. The indolochalcone 21 showed good binding
affinity for Aβ1-42 aggregates with a Ki < 10 nM. Replacement
of the iodo substituent with a chloro, bromo, methoxy, or di-
methylamino substituent all gave similar results, but replace-
ment with a fluoro, hydroxy, amino, or methylamino substituent
all reduced affinity to varying degrees. Autoradiography in
sections of brain tissue from an AD animal model showed that
21 specifically labeled Aβ plaques, but its efficacy was
hampered by low in vivo uptake into the brain (0.41% ID/g at
2 min) [15].
Conformationally restricted chalcones: flavones and
aurones
Flavones and aurones, such as 29a–c, 30a,b, 31a–c, 32, and
33a,b (Scheme 3A), can be classified as conformationally
restricted chalcone derivatives as their basic structures result
from insertion of an oxygen atom between the double bond and
Beilstein J. Org. Chem. 2013, 9, 1012–1044.
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Scheme 2: A. Structures of radiolabeled chalcone analogues discussed. B.–D. Synthetic schemes for the preparation of radiolabeled chalcones 19a
and 20a,b, and indolochalcone 21.
Table 1: Inhibition constants and biodistribution of radioactivity of fluorinated chalcone derivatives 18a–l and 19a,b (values are from [14]).
Compound n R1 R2 R3 Aβ1-42 Ki (nM) %ID/g at 2 min %ID/g at 30 min
18a 1 F Me Me 45.7 ± 7.1 — —
[11C]18a 1 F Me 11CH3 — 6.01 ± 0.61 2.26 ± 0.41
18b 2 F Me Me 20.0 ± 2.5 — —
[11C]18b 2 F Me 11CH3 — 4.73 ± 0.47 1.00 ± 0.19
18c 3 F Me Me 38.9 ± 4.2 — —
19a 3 18F Me Me — 3.48 ± 0.47 1.07 ± 0.17
19b 3 F Me 11CH3 — 4.31 ± 0.33 0.35 ± 0.03
18d 1 F H H 678.9 ± 21.7 — —
18e 2 F H H 1048.0 ± 114.3 — —
18f 3 F H H 790.0 ± 132.1 — —
18g 1 F H Me 197.1 ± 58.8 — —
18h 2 F H Me 216.4 ± 13.8 — —
18i 3 F H Me 470.9 ± 100.4 — —
18j 0 F Me Me 49.8 ± 6.2 — —
[11C]18j 0 F Me 11CH3 — 3.68 ± 0.35 1.04 ± 0.20
18k 0 F H H 663.0 ± 88.3 — —
18l 0 F H Me 234.2 ± 44.0 — —
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Scheme 3: A. Structures of the radiolabeled flavone and aurone analogues discussed. B. Synthetic scheme for the preparation of [18F]-labeled
flavone derivatives. C. Synthetic scheme for the preparation of the aurone scaffold and its [18F]- and [125I]-labeled analogues.
the phenyl ring attached to the carbonyl group of the chalcone
scaffold (Figure 1B, with oxygen atoms depicted in red). The
affinity of flavonoids towards Aβ aggregates was first estab-
lished by using fluorescence staining in brain sections of
Tg2576 transgenic mice [10]. The absence of spots in wild-type
mouse brain sections indicated the specificity of flavonoids
towards Aβ aggregates in AD mouse models. The [18F]-labeled
pegylated flavones 29a–c showed high affinity towards Aβ
Beilstein J. Org. Chem. 2013, 9, 1012–1044.
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Table 2: Inhibition constants and biodistribution of radioactivity of stilbene derivatives 44a–f and [11C]44d (values are from [22]).
Compound R1 R2 Aβ1-40 Ki (nM) %ID/g at 2 min %ID/g at 60 min
44a NO2 OMe 151 ± 30 — —
44b NH2 OMe 36 ± 5 — —
44c NHMe OMe 1.2 ± 0.5 — —
44d NHMe OH 6.0 ± 1.5 — —
[11C]44d NH11CH3 OH — 1.15 ± 0.08 0.30 ± 0.03
44e NMe2 OMe 1.3 ± 0.4 — —
44f NMe2 OH 2.2 ± 0.6 — —
aggregates with Ki values ranging between 5.3 nM for 29a and
19.3 nM for 29c (Scheme 3A) [16]. SAR studies suggest that, as
with chalcones, the tertiary amine in these flavones was impor-
tant for binding and tracing Aβ aggregates in mouse models, as
they consistently outperformed secondary and primary amine
analogues [16]. Also as with chalcones, the degree of pegyla-
tion had only minor effects on binding properties. Compounds
29a–c showed uptake rates indicative of high to sufficient levels
for brain imaging (2.89–4.17% ID/g at 2 min) and moderate
clearance rates [16]. The flavone backbone of 29a–c was built
by acylating 2-hydroxy-5-methoxyacetophenone (34) with
4-nitrobenzoyl chloride (35) and subjecting the resulting
2-acyloxyacetophenone (36) to Baker–Venkataraman rearrange-
ment [17] to afford the 1,3-diarylpropane-1,3-dione 37, which
was dehydrated with sulfuric acid to give 38. Subsequent nitro
reduction, reductive methylation, methyl ether cleavage, and
pegylation gave the nonlabeled precursors 39a–c. The [18F]-
label was introduced by using the standard [K/K222]18F in
DMSO and acetonitrile reaction conditions (Scheme 3B) [16].
The [Re]- and [99mTc]-labeled flavone complexes 30a and 30b
were also prepared by using the procedure described for the
synthesis of the [Re]- and [99mTc]-labeled chalcones 20a and
20b (Scheme 2). The [99mTc]-labeled flavone complex 30a
displayed high Aβ plaque affinity but limited brain uptake [18].
Aurone derivatives have been investigated for their Aβ plaque
binding affinity [19]. The [125I]-labeled methylamine aurone
31a presented great binding affinity to Aβ aggregates
(Ki = 1.2 nM), better than all reported flavones to date. It also
showed rapid brain uptake rate (3.17% ID/g at 2 min) and rapid
clearance (0.24% ID/g at 60 min) [19]. The effect of the tertiary
amine in this aurone scaffold was less pronounced than that
seen with chalcones or flavones. The dimethylamine analogue
of 31a had approximately six times weaker binding affinity,
while the free amine analogue showed only two times weaker
affinity. To further enhance the Aβ plaque traceability of 31a,
its methylamine moiety was replaced with ethylene oxide to
provide compound 31b, which exhibited a Ki value of 1.05 nM
in an in vitro binding assay [13]. The brain kinetics of 31b
(brain uptake = 4.51% ID/g at 2 min and washout = 0.09% ID/g
at 60 min) were found to be slightly better than those of 31a
[13]. Addition of 2 or 3 ethylene oxide units or replacement
with a hydroxy or methoxy group did not significantly improve
the plaque binding affinity and modestly affected the brain
kinetics. Replacement of the terminal hydroxy group of 31b
with a fluorine atom negatively affected the brain uptake prop-
erty of compound 31c (2.34% ID/g at 2 min) when compared to
31b [20]. However, it did not affect the washout character of
the compound. These results were confirmed by preparation and
analysis of the [18F]-labeled compound 32 [20]. In general, the
aurone derivatives 31a–c and 32 were built from the reaction of
methyl 5-iodosalicilate (40) with ethyl bromoacetate (41) fol-
lowed by ester hydrolysis and cyclization to afford 5-iodo-3-
coumaranone (42), which, after condensation with the proper
benzaldehydes, gave the aurone scaffold 43, which could be
radiolabeled (Scheme 3C). As for the chalcone and flavone
derivatives, [Re]- and [99mTc]-labeled aurone complexes 33a
and 33b were also prepared [18]. The high affinity for Aβ
aggregates observed with the [99mTc]-labeled aurone 33b was
hampered by its weak brain penetration, which made it unsuit-
able for in vivo application [18].
Stilbene and its analogues
Stilbene derivatives
The SARs of stilbene analogues, such as 44a–f, 45, and 46a,b
(Scheme 4A), as Aβ plaque tracers have been thoroughly
investigated. In general, it was found that an electron-donating
group at each end of the stilbene derivative is essential for Aβ
plaque binding affinity [21]. Analysis of stilbenes 44a–f shows
that a monomethylated or dimethylated amine at one end of the
stilbene core leads to strong binding affinity for Aβ1-40 aggre-
gates, while a free amine or nitro group reduces affinity. The
opposite end of the stilbene core can be substituted with a
hydroxy or methoxy substituent with little effect on binding
affinity (Table 2). Derivative 44d, which showed good affinity
towards Aβ aggregates in vitro (Ki = 6.0 ± 1.5 nM), has been
radiolabeled to give N-[11C]methylamino-4'-hydroxystilbene
([11C]44d), and this compound shows excellent labeling of Aβ
plaques in TgCRDN8 mouse brain sections by in vitro auto-
radiography [22].
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Scheme 4: A. Structures of the radiolabeled stilbene analogues discussed. B. Synthetic scheme for the preparation of [18F]BAY94-9172 (46a).
[18F]-Labeled stilbene derivatives have enhanced brain kinetics
rendering them appropriate for clinical use [23-25]. In order to
control the lipophilicity and keep the partition coefficient
(log P) value between 1 and 3, which reduces brain nonspecific
binding and improves signal-to-noise ratio, additional hydroxy
or ethylene oxide unit(s) were added [21]. An early fluorinated
stilbene was [18F]FMAPO (45), which demonstrated high
binding affinity for Aβ aggregates (Ki = 5.0 ± 1.2 nM) in assays
using human AD brain homogenates [26]. Even though addi-
tion of the fluoroalkyl side chain moiety had little effect on the
binding affinity and the clearance rate, it improved brain
kinetics significantly (from 1.15% ID/g at 2 min for [11C]44d
[22] to 9.75% ID/g at 2 min for 45 [26]). Florbetaben
([18F]BAY94-9172, 46a), another member of the stilbene class,
showed strong binding affinity for human AD brain
homogenates (Ki = 6.7 ± 0.3 nM) and promising pharmacoki-
netics [21], and this compound has progressed to clinical trials.
Compound 46a was tested clinically on 15 AD patients and a
similar number of healthy elderly volunteers [4]. Interestingly,
all AD patients showed widespread neocortical binding of 46a,
which was quantified by using the standardized uptake value
ratio (SUVR) technique [4]. This observation was further
supported by another study using a wider sample population
where AD patients demonstrated significantly higher SUVRs
when compared to healthy patients or patients with other neural
diseases such as Parkinson’s disease, mild cognitive impair-
ment, frontotemporal lobar degeneration, dementia with Lewy
bodies, and vascular dementia [27]. More recent phase 2/3 clin-
ical trials collectively showed that compound 46a displays a
high degree of sensitivity and selectivity in discriminating
between patients with probable AD and age-matched healthy
controls [28].
A pyridine analogue of 46a, florbetapir ([18F]AV-45, 46b) was
also prepared using a tosylate precursor with Sumitomo
modules for radiosynthesis [23,29]. Compound 46b displayed
strong affinity for Aβ peptides in AD brain homogenates (Ki =
2.87 ± 0.17 nM), excellent pharmacokinetics [30], and an
acceptable safety profile that paved the way to its clinical appli-
cation in brain imaging [31]. A number of 46b/PET studies
have been conducted [23,32-39]. Using 46b as an imaging
probe, PET indicated that the drug accumulates explicitly in
Aβ-deposition-rich cortical regions in AD patients with minimal
accumulation observed in healthy volunteers [40].
In general, the stilbene nucleus was built using the
Wadsworth–Emmons reaction,  and a representative
synthesis of stilbene 46a is shown (Scheme 4B). Initial
Wadsworth–Emmons reaction between diethyl (4-nitro-
benzyl)phosphonate (47) and 4-methoxybenzaldehyde (48)
constructed the stilbene core 49. The target compound 46 was
formed from a straightforward sequence of nitro reduction,
reductive methylation, methyl ether cleavage, pegylation and
radiolabeling. Several synthetic procedures have been described
for the preparation of 46a and its precursors in an effort to opti-
mize yield [21,41,42]. The best reported yield and purity was
obtained by mixing the mesylate precursor with the fluori-
nating agent in a modified PET-MF-2V-IT-1 synthesizer and by
Beilstein J. Org. Chem. 2013, 9, 1012–1044.
1020
Scheme 5: A. Structures of the diphenyl-1,3,4- and diphenyl-1,2,4-oxadiazoles discussed. B.,C. Synthetic schemes for the preparation of [125I]50a
and [125I]51c, respectively.
Table 3: Inhibition constants and biodistribution of radioactivity of the 2,5-diphenyl-1,3,4-oxadiazole derivatives 50a–f (values are from [47]).
Compound R Aβ1-42 Ki (nM) %ID/g at 10 min %ID/g at 60 min
50a NMe2 20.1 ± 2.5 — —
[125I]50a NMe2 — 5.93 ± 0.76 1.78 ± 0.41
50b OMe 46.1 ± 12.6 — —
[125I]50b OMe — 2.74 ± 0.37 0.36 ± 0.13
50c OH 229.6 ± 47.3 — —
50d OCH2CH2OH 282.2 ± 61.4 — —
50e (OCH2CH2)2OH 348.6 ± 51.7 — —
50f (OCH2CH2)3OH 257.7 ± 34.8 — —
purifying using plus C18 Sep-Pak cartridges [41]. In the prepar-
ation of [11C]44d, the [11C]-methylation of 4-amino-4'-
hydroxystilbene was carried out using the “LOOP” method, in
which trapping and reaction of [11C]CH3OTf with the appro-
priate stilbene analogue takes place inside an HPLC sample
loop [43].
Diphenyl-1,2,4- and diphenyl-1,3,4-oxadiazoles
The replacement of the stilbene ethylene linker with different
heterocycles is a common strategy in medicinal chemistry used
to improve the pharmacokinetics and/or pharmacodynamics of
stilbenes (Scheme 5A) [44-46]. In the case of Aβ probes, a
series of 2,5-diphenyl-1,3,4-oxadiazoles 50a–f and 3,5-
diphenyl-1,2,4-oxadiazoles 51a–e have been studied in this
respect (Table 3 and Table 4). Among the 2,5-diphenyl-1,3,4-
oxadiazoles, the dimethylamine analogue 50a (Ki = 20.1
± 2.5 nM) and methoxy analogue 50b (Ki = 46.1 ± 12.6 nM)
showed the best affinities towards Aβ aggregates, and radiola-
beling has been performed for both of these compounds. In
biodistribution studies, the dimethylamine analogue [125I]50a
showed good brain uptake and washout rates. Although
methoxy analogue [125I]50b showed poorer brain uptake, its
washout rate was increased compared to its dimethylamine
counterpart [47]. Interestingly, changing the heteroatom order
in the central ring from 1,3,4 (50a–f) to 1,2,4 (51a–e) has great
effects on both the physical characteristics and pharmacoki-
netics of the compounds. The 3,5-diphenyl-1,2,4-oxadiazole
analogue 51c was more lipophilic than its 1,3,4 counterpart 50a
(log P = 3.22 for 51c and 2.43 for 50a) [47]. In general, even
though 3,5-diphenyl-1,2,4-oxadiazoles 51a–e show excellent
affinity for Aβ aggregates in in vitro binding experiments
(Ki = 4.3–47.1 nM), they show poorer brain uptake rates
(1.07–2.06% ID/g at 2 min) and slower washout rates
(3.29–2.01% ID/g at 60 min) than their 1,3,4 counterparts [48].
Beilstein J. Org. Chem. 2013, 9, 1012–1044.
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Table 4: Inhibition constants and biodistribution of radioactivity of 3,5-diphenyl-1,2,4-oxadiazole derivatives 51a–e (values are from [48]).
Compound R Aβ1-42 Ki (nM) %ID/g at 2 min %ID/g at 60 min
51a NH2 14.2 ± 1.4 — —
[125I]51a NH2 — 1.61 ± 0.23 3.29 ± 0.58
51b NHMe 14.3 ± 3.6 — —
[125I]51b NHMe — 1.44 ± 0.12 2.70 ± 0.33
51c NMe2 15.4 ± 1.4 — —
[125I]51c NMe2 — 1.07 ± 0.23 2.32 ± 0.64
51d OMe 4.3 ± 2.1 — —
[125I]51d OMe — 2.06 ± 0.45 2.01 ± 0.33
51e OH 47.1 ± 4.1 — —
Figure 2: Structures of the radiolabeled benzothiazole analogues discussed.
These findings, together with the close structural similarities
between compounds 50a–f and 51a–e, highlight the importance
of lipophilicity as a factor in controlling brain kinetics [47].
Representative syntheses of radioiodinated oxadiazoles 50a and
51c are shown (Scheme 5B and C). The 1,3,4-oxadiazole core
of [125I]50a was obtained from the reaction between 4-iodo-
benzhydrazide (52) and 4-dimethylaminobenzaldehyde (23) in
the presence of ceric ammonium nitrate (CAN) followed by
subsequent radioiodination of compound 53 (Scheme 5B) [47].
The 1,2,4-oxadiazole core of [125I]51c was obtained by DCC/
HOBt-mediated condensation of 4-bromobenzamidoxime (54)
and p-nitrobenzoic acid (55). Subsequent nitro reduction,
reductive methylation, and radioiodination gave [125I]51c
(Scheme 5C) [48].
Thioflavin-T analogues
Benzothiazoles
Of all the amyloid imaging classes, the benzothiazoles, such as
56a–w, 57, 58a,b, and 59–65 (Figure 2), may well be one of the
most prolific and well-studied. The amyloid imaging dye
thioflavin-T (4, Figure 1) served as the inspiration for this
class of radiotracers in which the ionic charge was removed
to increase lipophilicity and to enhance in vivo BBB
Beilstein J. Org. Chem. 2013, 9, 1012–1044.
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permeability. Overall, this class of compounds shows high
affinity for Aβ aggregates with promising in vivo pharmacoki-
netics.
One  o f  the  ea r l i e s t  r ad io labe led  benzo th iazo les ,
[11C]6-Me-BTA-1 ([11C]56a; note: BTA = 2-(4'-methylamino-
phenyl)benzothiazole, Figure 2), was prepared by methylation
of 4-(6-methyl-2-benzothiazolyl)aniline using [11C]methyl
iodide [49]. Compared to 4, 56a showed greatly increased
lipophilicity and improved binding affinity for Aβ1-40
(Ki = 890 nM for 4 and Ki = 20.2 for 56a). In postmortem AD
brain sections, [11C]56a was able to stain both Aβ plaques and
neurofibrillary tangles (NFTs), while pharmacokinetic studies
in normal mice showed high brain uptake (7.61% ID/g at 2 min)
and good washout (2.76% ID/g at 30 min). Additional modifi-
cation of this scaffold by removal of the 6-Me group gave
[11C]BTA-1 ([11C]56b) [50]. Compound 56b was prepared by
coupling of p-nitrobenzoyl chloride (35) and 2-aminothio-
phenol (66) followed by nitro reduction to 67 and methylation
using [11C]methyl iodide (Scheme 6A). While showing a near
equal binding affinity for Aβ, the decreased lipophilicity of
[11C]56b to the ideal level led to improved pharmacokinetics
over [11C]56a as evidenced by improved uptake and washout
rates in normal mice (12.9% ID/g at 2 min and 1.7% ID/g at
30 min). Compound [11C]56b showed in vivo specificity for Aβ
in the brains of PS1/APP transgenic mice, and it was subse-
quently shown to bind specifically to amyloid deposits in
human AD brain homogenates [51].
The addition of a hydroxy group at the 6-position of [11C]56b
gave [11C]6-OH-BTA-1 ([11C]56c) [52]. Compound [11C]56c
was synthesized by first coupling p-anisidine (68) with
p-nitrobenzoyl chloride (35) to give the amide 69, which was
subsequently converted to the thioamide by using Lawesson’s
reagent and cyclized to form the benzothiazole core 70
(Scheme 6B). Demethylation with BBr3 and protection of the
resulting hydroxy moiety as the methoxymethyl (MOM) ether
gave 71. Reduction of the nitro group to 72, methylation using
[11C]methyl iodide, and cleavage of the MOM ether gave
[11C]56c. Compound 56c showed high affinity for Aβ1-40
(Ki = 4.3 nM) (Table 5). This synthesis has since been refined to
improve radiochemical yields and eliminate the need for a
protecting group by use of [11C]CH3OTf as the methylating
agent [53].
The 6-OH group of 56c made it less lipophilic than both 56a
and 56b and likely contributed to its moderate brain entry
(0.21% ID-kg/g at 2 min) but good clearance (0.018% ID-kg/g
at 30 min) in normal mice. Interesting SAR findings on this
scaffold from comparison of 56c–t (Table 5) included that the
more lipophilic secondary and tertiary amines at the 4'-position
were more potent (Ki) than primary amines. Also, in general,
substitution at the 6-position seemed to have only a small effect
in terms of Ki as 6-OH, -OCH3, -CN, and -Br gave similar
results. However, substitution at the 6-position had a larger
effect on pharmacokinetics in the brain, as 6-OH clearly gave
the best results [52]. As one of the most successful radiolabeled
Aβ imaging probes to date, [11C]56c has subsequently been
named Pittsburgh Compound B (PIB).
Additional studies of [11C]56c in humans have been promising
and suggest that PET imaging with this compound can provide
quantitative information on amyloid deposits in living patients.
In postmortem tissue, [11C]56c exhibited specific binding to the
amyloid-laden frontal cortex of the AD brain, but little binding
to the frontal cortex of the cognitively normal age-matched
control brain. Compound [11C]56c also displayed a rapid entry
and clearance in the brain of healthy controls, but a marked
retention in AD patients in areas of the brain known to contain
large amyloid deposits [54]. Additional data suggested that
[11C]56c was suitable for early detection of pathological
changes in AD patients before a significant loss of cognitive
function is apparent [55].
The impact of changing the position of the hydroxy group of
56c was investigated by synthesizing the 4-OH, 5-OH, and
7-OH analogues 56u–w using methods similar to those
described above [56]. The Ki values for these analogues in
human AD brain homogenates were between 11–19 nM, indi-
cating slightly reduced affinity compared to 56c (Ki = 2.8 nM)
(Table 6). However, each radiolabled analogue was able to stain
plaques in sections from transgenic AD mouse brain and human
AD brain. The 5-OH analogue [11C]56v showed the best phar-
macokinetic profile in normal mice with high brain uptake and a
washout rate, that was 8 times faster than that of [11C]56c.
Interestingly, it was noted that the 4-OH analogue 56u could
form an intramolecular hydrogen bond (i.e. an extra pseudo
ring), which could act to increase the lipophilicity of the com-
pound and lead to nonspecific binding and residual background
activity in the brain.
A [3H]-labeled analogue of 56c, AZD2184 (57), was also
synthesized to give a higher signal-to-background ratio by
virtue of its decreased lipophilicity [57]. This compound was
prepared through palladium catalyzed Suzuki coupling of the
starting halide 73 and boronic acid 74 followed by N-methyl-
ation of 75 with [3H]methyl iodide and O-demethylation with
sodium thiophenoxide (Scheme 6C). Compound 57 showed
high affinity for Aβ1-40 fibrils in vitro (Kd = 8.4 nM) and lower
background binding levels than 56c. While 57 was able to label
amyloid deposits in APP/PS1 mice, its brain penetration was
not as high as that of [11C]56c.
Beilstein J. Org. Chem. 2013, 9, 1012–1044.
1023
Scheme 6: A.–F. Synthetic schemes for the preparation of [11C]56b, [11C]56c, 57, 58a,b, 61, and [18F]65a–d.
Besides [11C], other radiolabels have been investigated for
benzothiazole imaging agents. Two of the earliest [125I]-labeled
imaging agents reported were [125I]TZDM (58a) and
[125I]TZPI (58b) [58]. The synthesis of these agents was
achieved in two steps by condensation of 5-bromo-2-aminoben-
zenethiol (76) and the appropriate benzaldehyde 77 followed by
radiolabeling of 78 (Scheme 6D). Both 58a and 58b showed
high affinity for Aβ1-40 and Aβ1-42 aggregates with Kd values
≤0.15 nM in all cases. However, pharmacokinetics for these
agents were less than ideal as both showed long retention in the
brains of normal mice, which is indicative of nonspecific
binding.
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Table 5: Inhibition constants and biodistribution of radioactivity of 6-substituted 2-arylbenzothiazole derivatives 56c–t (values are from [52]).
Compound R1 R2 Aβ1-40 Ki (nM) (%ID-kg)/g at 2 min (%ID-kg)/g at 30 min
56c 6-OH NHMe 4.3 — —
[11C]56c 6-OH NH11CH3 — 0.21 0.018
56d 6-OH NH2 46 — —
56e 6-OH NMe2 4.4 — —
[11C]56e 6-OH NMe11CH3 — 0.32 0.10
56f 6-H NHMe 11 — —
[11C]56f 6-H NH11CH3 — 0.43 0.057
56g 6-H NH2 37 — —
56h 6-H NMe2 4.0 — —
[11C]56h 6-H NMe11CH3 — 0.19 0.078
56i 6-Me NHMe 10 — —
[11C]56i 6-Me NH11CH3 — 0.22 0.083
56j 6-Me NH2 9.5 — —
56k 6-Me NMe2 64 — —
[11C]56k 6-Me NMe11CH3 — 0.078 0.15
56l 6-OMe NHMe 4.9 — —
[11C]56l 6-OMe NH11CH3 — 0.33 0.10
56m 6-OMe NH2 7.0 — —
[11C]56m 6-O11CH3 NH2 — 0.32 0.084
56n 6-OMe NMe2 1.9 — —
[11C]56n 6-OMe NMe11CH3 — 0.16 0.14
56o 6-CN NHMe 8.6 — —
[11C]56o 6-CN NH11CH3 — 0.32 0.063
56p 6-CN NH2 64 — —
56q 6-CN NMe2 11 — —
[11C]56q 6-CN NMe11CH3 — 0.24 0.097
56r 6-Br NHMe 1.7 — —
[11C]56r 6-Br NH11CH3 — 0.12 0.12
56s 6-Br NH2 7.2 — —
56t 6-Br NMe2 2.9 — —
[11C]56t 6-Br NMe11CH3 — 0.054 0.11
Table 6: Inhibition constants and biodistribution of radioactivity of hydroxy-substituted 2-arylbenzothiazole derivatives 56c,u–w (values are from [56]).
Compound R1 R2 human AD brainhomogenates Ki (nM)
%ID/g at 2 min %ID/g at 60 min
56c 6-OH NHMe 2.8 ± 0.5 — —
[11C]56c 6-OH NH11CH3 — 3.6 ± 1.4 0.6 ± 0.2
56u 4-OH NHMe 18.8 ± 3.8 — —
[11C]56u 4-OH NH11CH3 — 3.8 ± 0.9 0.3 ± 0.3
56v 5-OH NHMe 11.5 ± 3 — —
[11C]56v 5-OH NH11CH3 — 4.3 ± 0.45 0.09 ± 0.02
56w 7-OH NHMe 11.2 ± 5 — —
[11C]56w 7-OH NH11CH3 — 2.6 ± 0.76 0.16 ± 0.03
A series of iodinated benzothiazoles 59a–o was synthesized
using methods similar to those described above and SAR
studies were performed (Table 7) [59]. Among the interesting
findings was that the introduction of 3'-iodo increased
lipophilicity and binding to Aβ1-40 when R2 = NHMe.
However, the opposite effect on binding was observed when
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Table 7: Inhibition constants and biodistribution of radioactivity of iodinated 2-arylbenzothiazole derivatives 59a–o (values are from [59]).
Compound R1 R2 Aβ1-40 Ki (nM) %ID/g at 2 min %ID/g at 30 min
59a H NH2 8.32 — —
[125I]59a H NH2 — 9.08 3.4
59b H NHMe 4.94 — —
[125I]59b H NHMe — 4.40 2.68
59c H OH 19.1 — —
59d OH NH2 11.1 — —
[125I]59d OH NH2 — 5.64 0.36
59e OH NHMe 3.22 — —
[125I]59e OH NHMe — 7.76 2.66
59f OH OH 71.2 — —
59g OMe NH2 4.4 — —
59h OMe NHMe 1.93 — —
59i OMe OH 15.8 — —
59j NO2 NH2 4.6 — —
59k NO2 NHMe 1 — —
59l Br NH2 0.67 — —
59m Br NHMe 1.6 — —
59n OCH2OCH3 NH2 15.1 — —
59o CO2Me NH2 3.34 — —
R2 = OH. Among the [125I]-labeled derivatives, more polar
compounds exhibited better clearance and less nonspecific
binding in the brains of normal mice, a typical result for brain
imaging probes. One of the most promising compounds identi-
fied in this study was [125I]59d.
The [125I]-labeled benzothiazole bithiophene 60 was synthe-
sized by condensation of 5-bromo-2-aminobenzenethiol and
2,2'-bithiophene-5-carbaldehyde followed by installation of the
radiolabel. In in vitro binding experiments, 60 displayed high
affinity for both Aβ1-40 and Aβ1-42 aggregates with Ki values of
0.25 nM and 0.31 nM, respectively. In addition, it was used to
clearly visualize Aβ plaques in AD brain sections and showed
favorable pharmacokinetics in the brain with high uptake
(3.42% ID/g at 2 min) and fast washout (0.53% ID/g at 60 min).
The [125I]-labeled phenyldiazenyl benzothiazole 61 was
prepared via a diazo coupling reaction between 79 and 80 to
give 81 followed by installation of the radiolabel (Scheme 6E)
[60]. Interestingly, in in vitro binding experiments, 61 displayed
higher affinity for tau aggregates (Ki = 0.48 nM) than for Aβ
aggregates (Ki = 8.24 nM). Although it was used to clearly visu-
alize NFTs in AD brain sections, further modifications will be
necessary to improve the pharmacokinetics of this compound in
the brain, as it showed particularly slow washout rate (2.89%
ID/g at 60 min).
Three [18F]-labeled analogues of 56c, [18F]O-FEt-PIB (62),
[18F]FBTA (63), and [18F]3'-F-PIB ([18F]GE067, 64) were also
prepared. Compound 62 was synthesized by using the hydroxy
group of 56c to displace the tosylate of [18F]fluoroethyltosylate.
Compound 62 had a Ki value of 0.17 nM for AD brain
homogenate and was able to stain Aβ plaques in postmortem
AD brain [61]. Although its biodistribution was not as good as
that of 56c, 62 still showed promise in an in vivo study using a
rat model of AD [62]. Moving the [18F]fluoroethoxy substituent
of 62 from the 6-position to the 3'-position resulted in a low
binding affinity for Aβ and an inability to stain plaques in post-
mortem AD brain [63]. In compound 63, the [11C]methylamino
group of [11C]56c was replaced by a [18F]fluoroethylamino
group, and, while this compound showed better binding affinity
than 56c ,  i t s  brain  pharmacokinet ics  were not  as
good [64]. Compound 64 also showed promising results in
whole-body biodistribution and radiation dosimetry studies
[65].
A series of fluorinated benzothiazoles 65a–e was synthesized
by direct substitution of the nitro group of a key synthetic inter-
mediate 82 (prepared using synthetic steps already describe for
[11C]56c) by an [18F] atom (Scheme 6F) [66,67]. Compounds
65a,b,d (R = H, Me, and OMe) all showed high binding affinity
for AD brain homogenates with Ki values below 10 nM, which
is comparable to that of 56c in the same assay, while 65c
(R = OH) showed slightly reduced affinity (Table 8). In addi-
tion to showing a promising ability to stain Aβ plaques in vivo,
[18F]65a,b showed high brain uptake and rapid washout in
normal mice. In fact, each of these compounds displayed better
pharmacokinetics than [11C]56c in the same assay.
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Table 8: Inhibition constants and biodistribution of radioactivity of fluorinated 2-arylbenzothiazole derivatives 65a–e (values are from [66,67]).
Compound R human AD brain homogenates Ki (nM) %ID/g at 2 min %ID/g at 30 min
65a H 9.0 ± 2.0 — —
[18F]65a H — 3.20 ± 0.38 0.21 ± 0.03
65b Me 5.7 ± 1.8 — —
[18F]65b Me — 5.33 ± 0.74 0.27 ± 0.06
65c OH 22.5 ± 4.5 — —
[18F]65c OH — 4.70 ± 0.48 0.57 ± 0.36
65d OMe 2.2 ± 0.5 — —
[18F]65d OMe — 5.10 ± 0.40 0.43 ± 0.12
65e CO2H >4000 — —
Figure 3: Structures of the radiolabeled benzoxazole analogues discussed.
Benzothiazole probes such as 83a,b and 84a,b labeled with
[Re] and [99mTc] were also synthesized (Scheme 7A) [68,69].
[Re] and [99mTc]MAMA-BTA (83a and 83b; MAMA = mono-
amine-monoamide bisthiol-BTA) were prepared by first linking
2-(4-nitrophenyl)-6-hydroxybenzothiazole (85) via 1,5-dibro-
mopentane (86) to monoamine-monoamide bisthiol protected
with p-methoxy benzyl (MAMA-PMB, 87) to give 88
(Scheme 7B) [68]. Nitro reduction of 88 followed by thioether
deprotection gave MAMA-BTA (89), which was labeled
through reaction with the [Re] (used for in vitro studies) or
[99mTc] precursors to give the desired 83a,b. [Re] and
[99mTc]BAT-BTA (84a and 84b; note: BAT = bis(amino-
ethanethiol)) were prepared by addition of ethyl bromoacetate
(41) to the unprotected amine of the S,S'-bis-trityl-N-Boc-1,2-
ethylenedicysteamine chelating agent (90) followed by saponifi-
cation that gave the free acid intermediate 91, which was
coupled with 2-(4-aminophenyl)-1,3-benzothiazole (92)
(prepared from 2-aminothiophenol (66) and 4-aminobenzoic
acid (93)) by using EDCI·HCl and HOBt (Scheme 7C) [69].
Deprotection followed by reaction with the [Re] or [99mTc]
precursors gave 84a and 84b. While both 83a and 84a showed
promise as in vitro Aβ labeling agents, the [99mTc] analogues
83b and 84b exhibited problems in pharmacokinetic studies in
vivo. Compound 83b showed sufficient initial uptake (1.34%
ID/g at 2 min), but delayed washout (0.65% ID/g at 60 min) in
normal mice, while 84b was unable to cross the BBB to a suffi-
cient degree.
Benzoxazoles
Replacement of the sulfur of the benzothiazole backbone by
oxygen affords the benzoxazole backbone. Compounds 94,
95a–n, and 96–99 (Figure 3) have also been successfully
employed for radioimaging of Aβ plaques. The isosteric
replacement of the sulfur of [125I]TZDM (58a) with an oxygen
was designed to decrease molecular weight and increase
lipophilicity and afforded [125I]IBOX (94) [70]. Compound 94
was prepared via boric acid catalyzed condensation of 5-nitro-2-
aminophenol (100) and 4-dimethylaminobenzoic acid (101) to
give the nitro intermediate 102, which was reduced through
catalytic hydrogenation to the amine (Scheme 8A).
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Scheme 7: A. Structures of the [Re]- and [99mTc]-labeled benzothiazole analogues discussed. B.,C. Synthetic schemes for the preparation of 83a,b
and 84a,b.
Subsequent conversion to the diazonium ion and displacement
with iodide ion gave IBOX, which was radiolabeled to
give 94. Compound 94 showed similar affinity for Aβ1-40
aggregates when compared to 58a ,  and it  was able
to label Aβ plaques in postmortem AD brain sections.
Importantly, 94  showed superior peak brain uptake
(2.08% ID/g at 30 min) and faster brain washout than 58a in
normal mice.
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Scheme 8: A.–E. Synthetic schemes for the preparation of 94, [123I]95e, 96–98.
Expanding on this 2-arylbenzoxazole scaffold, a series of
benzamide-substituted 2-arylbenzoxazoles 95a–n was synthe-
sized [71]. A representative synthesis of [123I]95e is shown
(Scheme 8B). Boric acid catalyzed condensation of 4-nitro-2-
aminophenol (103) and 4-dimethylaminobenzoic acid (101)
gave the nitro intermediate 104. Catalytic hydrogenation as
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above gave the amine intermediate, and subsequent reaction
with 4-iodobenzoyl chloride (105) and installation of the radio-
label gave the target compound. SAR analysis of the com-
pounds indicates that the benzamide moiety is favored at pos-
ition 5 rather than 6 of the benzoxazole core in terms of binding
affinity for Aβ plaques in vitro (Table 9). The best compound
was 95e, which had a Ki value of 9.3 nM, but [123I]95e was
unable to cross the BBB in vivo. This disappointing result could
be appointed to the excessively high lipophilicity of the com-
pound.
Table 9: Inhibition constants of benzamide-substituted 2-arylbenzoxa-
zole derivatives 95a–n (values are from [71]).
Compound R Ki (nM)
95a 5-phenyl 12.0
95b 6-phenyl 26.0
95c 5-(3,4,5-trimethoxyphenyl) 109
95d 6-(3,4,5-trimethoxyphenyl) 628
95e 5-(4-iodophenyl) 9.3
95f 6-(4-iodophenyl) 60.1
95g 5-(p-tolyl) 13.2
95h 6-(p-tolyl) 86.0
95i 5-(m-tolyl) 13.4
95j 6-(m-tolyl) 31.5
95k 5-(o-tolyl) 18.9
95l 6-(o-tolyl) 112
95m 5-(3,4-(methylenedioxy)phenyl) 17.2
95n 6-(3,4-(methylenedioxy)phenyl) 19.7
To improve the pharmacokinetic profile of 94, the [18F]-labeled
analogue 96 was designed as an imaging probe [72]. Com-
pound 96, which contains an [18F] end-capped polyethylene
glycol chain at position 5 of the benzoxazole core in place of
the [125I] of 94 at position 6 to reduce lipophilicity, was
prepared by polyphosphoric acid catalyzed condensation of
2-amino-4-methoxyphenol (106) and 4-monomethylaminoben-
zoic acid (107) to give the benzoxazole core, which was
O-demethylated to give 108 (Scheme 8C). Subsequent coupling
with 2-[2-(2-chloroethoxy)ethoxy]ethanol (109) gave 110.
TBDMS protection of the alcohol and Boc protection of the
amine gave 111. Finally, TBAF cleavage, installation of the
radiolabel, and acid cleavage gave 96. Compound 96 showed
good affinity for Aβ1-42 (Ki = 9.3 nM). This compound also
showed promising pharmacokinetics in normal mice, with
greatly improved uptake and washout rates compared to 94, and
it successfully labeled Aβ plaques in vitro. In addition,
it  showed increased retention in vivo in transgenic
AD mice compared to wild-type. A N,N-dimethyl derivative
was also synthesized, and, while it too showed good affinity
for Aβ1-42, its increased lipophilicity compared to the
monomethyl compound gave slightly worse pharmacokinetic
properties.
The [11C]-labeled styrylbenzoxazole [11C]BF-145 (97) and the
related [18F]-labeled styrylbenzoxazole [18F]BF-168 (98) were
prepared and studied for Aβ imaging [73-75]. The simple two-
step synthesis of 97 used polyphosphoric acid trimethylsilyl
ester (PPSE) catalyzed condensation of 4-fluoro-2-aminophenol
(112) with a cinnamic acid 113 to give the benzoxazole core
followed by conversion to the primary amine 114 and radiola-
beling (Scheme 8D). The synthesis of 98 was more complex
and began with a reaction between 2-methyl-6-methoxybenz-
oxazole (115) and 4-((N-Boc-N-methyl)amino)benzaldehyde
(116) followed by a dehydration reaction to give 117
(Scheme 8E). Subsequent removal of the Boc group
followed by installation of a trifluoroacetamide and
O-demethylation gave the intermediate 118 used in a Mitsunobu
reaction with 2-hydroxyethyl tosylate (119). Amine deprotec-
tion to 120 and installation of the [18F] label gave the target
compound 98.
Both 97 and 98 showed good affinity for Aβ1-42 aggregates
(Ki = 4.5 nM and 6.4 nM, respectively). Interestingly, while 98
was able to selectively stain senile plaques (SPs) and NFTs in
AD brain sections, 97 was only able to stain SPs. In addition, 97
and 98 showed substantial brain uptake and fast washout (4.4%
and 3.9% ID/g at 2 min and 1.6% and 1.6% ID/g at 30 min, res-
pectively) with promising in vivo imaging results in transgenic
mice.
Building on the promising results of 97 and 98, an optimized
derivative, [11C]BF-227 (99), was studied for Aβ imaging. The
key difference in 99 is the replacement of a phenyl ring with a
thiazole ring. Compound 99 demonstrated good affinity for syn-
thetic Aβ1-42 aggregates (Ki = 4.3 nM), rapid uptake (7.9% ID/g
at 2 min) and clearance (0.64% ID/g at 60 min) in normal mice,
the ability to selectively stain Aβ plaques in AD brain sections,
and promising results in a clinical PET study in AD patients
[76]. Additional studies suggest that 99 has the possibility to be
useful for early detection of AD and also for predicting progres-
sion from mild cognitive impairment to AD [77,78]. Interest-
ingly, 99 has also shown promise for diseases other than AD. It
has been suggested that 99 may provide a means of diagnosis
and disease monitoring in transmissible spongiform
encephalopathies [79] and may be useful for monitoring
α-synuclein deposits in conditions such as multiple system
atrophy and Parkinson’s disease [80]. A version of 99 labeled
with [18F] rather than [11C] has also been proposed for use in
Parkinson’s disease [81].
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Figure 4: Structures of the radiolabeled benzofuran analogues discussed.
Table 10: Inhibition constants and biodistribution of the radioactivity of iodinated 2-arylbenzofuran derivatives 122a–e (values are from [83]).
Compound R1 R2 Aβ1-40 Ki (nM) %ID at 2 min %ID at 60 min
122a 5-iodo NMe2 7.7 ± 1.2 — —
[125I]122a 5-iodo NMe2 — 0.51 ± 0.05 1.08 ± 0.15
122b 5-iodo NHMe 1.1 ± 0.2 — —
[125I]122b 5-iodo NHMe — 0.78 ± 0.06 1.20 ± 0.34
122c 5-iodo OMe 4.2 ± 0.8 — —
122d 5-iodo OH 6.5 ± 0.2 — —
[125I]122d 5-iodo OH — 1.40 ± 0.04 1.51 ± 0.20
122e 6-iodo NMe2 0.4 ± 0.1 — —
[125I]122e 6-iodo NMe2 — 0.48 ± 0.07 1.00 ± 0.22
Benzofurans
Replacement of the nitrogen of the benzoxazole backbone with
carbon affords the benzofuran backbone of compounds
121–126 (Figure 4), which has also been successfully employed
for radioimaging of Aβ plaques. The [11C]-labeled benzofuran
121 was prepared via Wittig reaction between the triphenyl-
phosphonium salt of 2-hydroxy-5-methoxybenzyl alcohol (127)
and 4-nitrobenzoyl chloride (35) to give 128 followed by nitro
reduction and O-demethylation to give 129 and radiolabeling
(Scheme 9A). Using AD brain gray matter homogenates, com-
pound 121 showed good binding affinity for Aβ plaques
(Ki = 0.7 nM) and was able to stain both SPs and NFTs in vitro.
In normal mice, this compound showed rapid uptake (4.8% ID/
g at 2 min) and fast washout (0.2% ID/g at 60 min). In vivo
plaque labeling in APP transgenic mice was also successful
[82].
Using similar chemistry as described above, a series of iodi-
nated 2-arylbenzofurans 122a–e was prepared and studied [83].
A representative synthesis of [125I]122a, which uses a similar
Wittig as in the synthesis of 121, is shown in Scheme 9A. It was
found that the iodo substituent could be varied between the 5-
and 6-positions, and the N,N-dimethylamino substituent could
be changed to a secondary methylamino or hydroxy moiety
with little effect on binding affinity for synthetic Aβ1-40, as all
compounds had a Ki ≤ 8 nM (Table 10). While the [125I]-
labeled benzofurans in this series showed good brain uptake in
normal mice, their washout was rather slow indicating nonspe-
cific binding in vivo.
Several [18F]-labeled benzofurans have been employed with
success for Aβ imaging. [18F]FPYBF-1 (123a), which has a
N,N-dimethyl-2-aminopyridine group attached to the benzo-
furan core, was synthesized via Suzuki coupling between
5-methoxybenzofuran-2-boronic acid (130) and 2-amino-5-
iodopyridine (131) to give 132, which was followed by reduc-
tive amination and O-demethylation to give 133 (Scheme 9B).
Finally, reaction with 2-[2-(2-chloroethoxy)ethoxy]ethanol
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Scheme 9: A.–E. Synthetic schemes for the preparation of 121, [125I]122a, 123a,b, 125a,b, and 126.
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(134) followed by radiolabeling gave 123a. This compound
showed high affinity for Aβ1-42 aggregates (Ki = 0.9 nM), the
ability to label plaques in postmortem AD brains, and suitable
pharmacokinetic properties in normal mice (5.16% ID/g at
2 min and 2.44% ID/g at 60 min). In addition, it showed good in
vivo binding to plaques in transgenic mice [84]. A closely
related compound, [18F]FPHBF-1 (123b), which has a N,N-
dimethylaniline group in place of the N,N-dimethylamino-
pyridine group, was prepared using a Wittig reaction between
the triphenylphosphonium salt of 2-hydroxy-5-methoxybenzyl
alcohol (127) and 4-dimethylaminobenzoyl chloride (35), fol-
lowed by O-demethylation and installation of the [18F]-labeled
linker (Scheme 9C). Like 123a, compound 123b showed good
affinity for Aβ aggregates in vitro and in vivo. However, its
slow washout from the brain, which can be attributed to its
increased lipophilicity compared to 123a, indicated that addi-
tional refinements will be needed [85].
Derivatives of 123a and 123b were also prepared [86]. These
compounds, [18F]FPYBF-2 (123c) and [18F]FPHBF-2 (123d),
have a secondary methylamino group in place of the dimethyl-
amino group. Introduction of the secondary amine served to
reduce lipophilicity. In addition, as the secondary amines are
less rapidly metabolized than the tertiary amines, they may help
improve the stability of these compounds in vivo. The syn-
thesis of these derivatives used methodology similar to that
already described for 123a and 123b. One key difference,
however, was the need for orthogonal TBS and Boc protection/
deprotection to prevent the secondary amine from reacting with
the MsCl used to introduce the radiolabel. Both 123c and 123d
showed good affinity for Aβ1-42 aggregates (Ki = 2.41 nM and
3.85 nM, respectively) as well as the ability to label plaques in
transgenic mice. Also, both 123c and 123d showed high uptake
and rapid washout with improved pharmacokinetic properties
when compared to 123a and 123b.
The [3H]-labeled AZD4694 (124) also showed promise for Aβ
imaging [87]. With good affinity for β-amyloid fibrils in vitro
(Kd = 2.3 nM), this compound was able to label plaques in
human AD brain sections with little nonspecific binding. In ad-
dition, the good pharmacokinetic profile of 124 warrants further
investigation in vivo.
[Re] and [99mTc]-labeled benzofurans, BAT-Bp-2 (125a,b),
were synthesized from 132 by reductive monoamination and
O-demethylation to give 135 (Scheme 9D) [88]. Subsequent
reaction with the protected chelation ligand TRT-Boc-BAT-Br
(136) and labeling through reaction with the rhenium (used for
in vitro studies) and technetium precursors gave compounds
125a and 125b, respectively. Compound 125b showed decent
affinity for Aβ1-42 aggregates (Ki = 32.8 nM) in vitro, although,
by comparison to other benzofuran probes of similar structure,
it was clear that introduction of the BAT chelator decreased
binding affinity. In contrast to other [99mTc]-labeled Aβ probes,
125b showed decent brain uptake and washout rates in normal
mice (1.80% ID/g at 2 min and 0.79% ID/g at 60 min). In addi-
tion, it was able to label Aβ plaques in vivo in transgenic mice,
a first for a [99mTc]-labeled Aβ probe.
The [125I]-labeled probe 126 contains the benzofuran core, but
could also be classified as a chalcone, specifically a chalcone in
which the conformation around the double bond is fixed [89].
Compound 126 was synthesized by using a Rap–Stoermer con-
densation between the bromo-substituted salicylaldehyde (137)
and α-brominated 4-nitroacetophenone (138) to form the benzo-
furan core (Scheme 9E). Nitro reduction followed by methyl-
ation gave 139, and radiolabeling gave 126. This compound
showed good affinity for Aβ1-42 aggregates (Ki = 6.6 nM). Sec-
ondary methylamino and primary amino derivatives showed
decreased binding affinity and poorer labeling of plaques in
brain sections from transgenic mice. While the pharmacoki-
netics of this compound in normal mice were promising (3.53%
ID/g at 2 min and 0.87% ID/g at 60 min), they were not as good
as those previously reported for [125I]-labeled N,N-dimethyl-
amino chalcones and aurones.
Imidazopyridines
The imidazopyridine core has also been used in developing
novel Aβ imaging agents such as 140–142 (Scheme 10A).
Initial SAR studies were based on derivatives 140a–j. One of
the most successful imidazopyridines studied to date has been
[125I]IMPY ([125I]140e). Representative of this scaffold, the
synthesis of [125I]140e used a fusion reaction between 2-amino-
5-iodopyridine (143) and an α-bromoacetophenone 144 to form
140e, which was then radiolabeled (Scheme 10B) [90]. This
preparation has since been improved by Kung et al. who,
through the use of a reverse-phase C4 minicolumn with step-
wise washing and elution, have simplified the purification
process by eliminating the need for HPLC purification [91].
While 140e showed good affinity for Aβ1-40 aggregates
(Ki = 15.0 nM), SAR analysis demonstrated that, in general,
other modifications to the scaffold were not well tolerated and
reduced the binding affinity (Table 11). An exception was the
replacement of the 6-iodo substituent with a bromine, as 140f
showed similar affinity to the parent compound [90].
In addition to its good binding affinity for Aβ, [125I]140e
showed other promising properties for use as an imaging probe.
For example, it selectively labeled plaques in postmortem AD
brain sections and showed plaque labeling with low back-
ground activity in a transgenic mouse model. The pharmacoki-
netics of [125I]140e were also promising. It showed high uptake
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Scheme 10: A. Structures of the radiolabeled imidazopyridine analogues discussed. B. Synthetic scheme for the preparation of [125I]140e and 142.
Table 11: Inhibition constants and biodistribution of radioactivity of 2-arylimidazopyridine derivatives 140a–j (values are from [90]).
Compound R1 R2 R3 Aβ1-40 Ki (nM) %ID at 2 min %ID at 60 min
140a H H NHMe >1000 — —
140b H H NMe2 >2000 — —
140c Me H NHMe >2000 — —
140d Me H NMe2 242 ± 20 — —
140e I H NMe2 15 ± 5 — —
[125I]140e 125I H NMe2 — 2.88 ± 0.25 0.21 ± 0.03
140f Br H NMe2 10.3 ± 1.2 — —
140g Me H Br 638 ± 30 — —
140h NMe2 H Br 339 ± 40 — —
140i H I NMe2 >2000 — —
140j I I NMe2 >2000 — —
(2.9% ID/g at 2 min) and fast washout (0.2% ID/g at 60 min) in
normal mice. These kinetic properties represented improve-
ments over both 58a and 94 [92]. Safety, biodistribution, and
dosimetry studies of [123I]IMPY, the [123I]-labeled counterpart
of 140e, have indicated it may be a safe radiotracer with appro-
priate pharmacokinetics for use in AD patients [93].
More in depth SAR studies of the imidazopyridine scaffold
have been conducted by synthesizing the series of analogues
141a–w [94]. The effect of different substituents on binding
affinity (Ki) for human Aβ plaques was examined (Table 12). In
general, it was found that the N,N-dimethylamino analogues
(R1 = R2 = Me) had higher binding affinity for human Aβ
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Table 12: Inhibition constants of 2-arylimidazopyridine derivatives 141a–w (values are from [94]).
Compound R1 R2 R3 R4 R5 human AD brain homogenates Ki(nM)
140e Me Me H I H 8.9 ± 0.7
141a Me Me H Br H 5.9 ± 0.4
141b Me Me H Cl H 24.2 ± 5.6
141c Me Me H F H 13.0 ± 1.6
141d Me Me H CN H 8.2 ± 1.0
141e Me Me H NO2 H 7.6 ± 0.7
141f Me Me H OMe H 38.5 ± 5.0
141g Me Me H SEt H 8.3 ± 0.5
141h Me Me H Br I 183 ± 61
141i Me Me H Br CN >180
141j Me Me H OH H 177 ± 31
141k CF3CO Me Br Br H >1000
141l CF3CO H Me Br H >1000
141m MeCO Me Me Br H >1000
141n H Me Br Br H 7.4 ± 0.6
141o H H Me Br H 658 ± 47
141p H Me Me Br H >1000
141q H Me H SCH2CONH2 H 1840 ± 497
141r H Me H S(CH2)2OH H 645 ± 75
141s Me Me H SCH2CONH2 H 391 ± 76
141t Me Me H SCH2C6H4-p-OMe H 8.3 ± 1.8
141u Me Me H S(CH2)2OH H 88 ± 6
141v H Me Me SCH2CONH2 H >1000
141w H Me Me S(CH2)2OH H >1000
plaques than did the secondary methylamino analogues
(R1 = H, R2 = Me). Little tolerance for substitution at both R3
and R5 was seen, as the most potent compounds almost always
had a hydrogen atom at these positions. One exception was
observed with the secondary methylamino analogue when
R3 = Br, as 141n showed high affinity. For R4 it was seen that
polarizable or electron-withdrawing substituents showed higher
affinity than strongly electron-donating substituents. In addi-
tion, it was observed that bulky, hydrophobic thioether
substituents (such as R4 = SCH2C6H4-p-OMe) were well toler-
ated at this position. This finding was of particular interest as it
provided a possible means of generating new PET ligands via
[11C]- or [18F]-labeling through S-alkylation.
The [18F]-labeled imidazopyridine, [18F]FPPIP (142), was
prepared starting from 140e. A palladium-catalyzed coupling
with tributyl(vinyl)tin to give an alkene intermediate was fol-
lowed by hydroboration-oxidation to give the hydroxypropyl
intermediate 145, which was radiolabeled to give 142
(Scheme 10B). This compound showed good binding affinity
for Aβ (Ki = 48.3 nM) in using human AD cortical tissues, as
well as specific labeling of Aβ plaques in postmortem AD
brain. This, coupled with favorable pharmacokinetics observed
in a normal rhesus monkey, made 142 a promising compound
[95]. However, another [18F]-labeled imidazopyridine,
[18F]FPM-IMPY, has shown less promising results. This com-
pound, in which one of the N-methyl groups of IMPY was
replaced with a [18F]fluoropropyl moiety, showed lower
binding affinity than IMPY and poor pharmacokinetics [96].
Benzimidazoles
The benzimidazole scaffold is highly similar to the imidazopyri-
dine scaffold, but the benzimidazole ring has reduced
lipophilicity when compared to imidazopyridines. This has the
potential to reduce nonspecific binding and enhance signal-to-
noise ratio. The [125I]-labeled benzimidazole analogue of 140e,
compound 146 ,  was prepared through cyclization of
4-bromobenzene-1,2-diamine (147) and p-dimethylaminobenz-
aldehyde (23) to give 148 followed by installation of the radio-
label (Scheme 11) [97]. Compound 146 showed good
binding affinity for Aβ1-42 aggregates (Ki = 9.8 nM), as
well as high uptake and rapid clearance in normal mice
(4.14% ID/g at 2 min and 0.15% ID/g at 60 min). In vitro
labeling of Aβ plaques in AD brain sections showed a strong
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Scheme 11: Synthetic scheme for the preparation of the benzimidazole 146.
Figure 5: Structures of the quinolines discussed.
signal with low background, and in vivo plaque labeling in
transgenic mice was also successful. However, this scaffold is
lacking in detailed SAR analysis compared to the imidazopyri-
dine scaffold.
Quinoline and naphthalene analogues
Quinolines
Investigation of the quinoline scaffold for imaging in AD has
yielded some interesting results, despite there only being a few
examples in the literature. The [18F]-labeled 2-fluoroquinolin-8-
ol [18F]CABS13 (149) has recently been reported (Figure 5)
[98]. The straightforward synthesis of this compound began
with benzyl protection of 2-chloroquinolin-8-ol followed by
installation of the [18F]-label and Pd-catalyzed hydrogenolysis
to give the target compound. Compound 149 potently bound to
Aβ-Zn aggregates (Kd = 1.5 nM) and showed rapid uptake and
washout in normal mice (10% ID/g at 2 min and 1.1% ID/g at
30 min). Also, delayed washout of 149 was observed in APP/
Ps1 transgenic mice, which was indicative of non-specific
binding to Aβ plaques. However, two other quinoline probes,
[11C]BF-158 (150) and [18F]THK523 (151), had high affinity
for tau pathology as opposed to Aβ. Compound 150 showed
good uptake and washout in normal mice (11.3% ID/g at 2 min
and 2.1% ID/g at 60 min), and was able to label NFTs in post-
mortem AD brain section while only faintly staining plaques
[99]. Compound 151 showed high affinity (Kd = 1.7 nM) and
selectivity for recombinant tau fibrils in vitro, and, with favor-
able pharmacokinetics, it was able to highlight tau pathology in
vivo in transgenic mice [100].
Naphthalenes
Replacement of the cyclic nitrogen in the quinoline scaffold
described in the previous section affords the naphthalene scaf-
fold. This scaffold has shown promising results for Aβ imaging,
particularly [18F]FDDNP (152), although this scaffold is also
represented by only a few examples in the literature. Com-
pound 152 was prepared starting from 1-(6-hydroxy-2-naph-
thyl)-1-ethanone (153) via a Bucherer reaction with 2-(methyl-
amino)ethanol (154) followed by Knoevenagel reaction of 155
with malononitrile (156) and [18F] labeling of 157 (Scheme 12)
[101,102]. Compound 152 bound to synthetic Aβ1-40 fibrils
with high affinity (Kd = 0.12 nM) and crossed the BBB [103].
In addition, PET imaging studies using 152 demonstrated the
ability of this compound to determine the localization and
load of both SPs and NFTs in living AD patients [104], as
well as the ability to differentiate between patients with no
cognitive impairment, mild cognitive impairment, and AD
[105].
[Re]- and [99mTc]-labeled derivatives of 152 have also been
prepared by bromination of 157 with NBS to give 158 followed
by conjugation with MAMA-PMB (87) and deprotection with
acid to give 159. Reaction with the technetium or rhenium
precursors gave the target derivatives 160a,b (Scheme 12)
[106]. In vitro binding studies with the [Re]-labeled compound
160a showed a 14-fold decrease in binding affinity for Aβ1-42
aggregates compared to 152. In addition, the [99mTc]-labeled
compound 160b showed very low brain uptake in normal mice
indicating the need for additional refinements of this compound.
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Scheme 12: Synthetic scheme for the preparation of the naphthalene analogues 152 and 160a,b.
Combination of known scaffolds
With the success of the benzothiazole and imidazopyridine scaf-
folds for Aβ imaging, it was logical to suspect that combination
of the two scaffolds into a single molecule could also provide a
good imaging agent. Examples of this combination scaffold can
be seen in compounds 161–164 (Scheme 13A). IBT (161) was
prepared by direct coupling of 6-methoxybenzo[d]thiazol-2-
amine (165) and the nitro substituted α-bromoacetophenone 138
to give 166 followed by installation of the radiolabel
(Scheme 13B) [107]. Compound 161 showed good affinity for
both Aβ1-40 and Aβ1-42 (Ki = 3.5 nM and 5.8 nM, respectively)
and was comparable to compound 56c in the same assay. The
pharmacokinetics of this compound were also similar to those
of [11C]56c. In vivo specific plaque labeling by compound 161
was confirmed through studies in APP/Ps1 transgenic mice.
Derivatives of this combination scaffold 162a–n were also
investigated (Table 13) [108]. Of note was derivative 162i in
which the secondary methylamino group of 161 has been
replaced with iodine. This derivative showed high affinity for
Aβ1-40 (Kd = 10.9 nM), and the iodo substituent could readily
be radiolabeled. However, the high lipophilicity of this com-
pound may lead to nonspecific plaque labeling in vivo.
The [125I]-labeled styrylindole 163 and styrylquinoline 164
scaffolds synthesized by Yang et al. can be thought of as stil-
bene combination scaffolds [109]. The synthesis of the [125I]-
labeled styrylindole 163 used a Wittig reaction between the
triphenyl phosphonium ylide 167 and 1H-indole-5-carbalde-
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Scheme 13: A. Structures of the radiolabeled analogues resulting from the combination of various scaffolds. B.,C. Synthetic schemes for the prepar-
ation of 161 and 163.
Table 13: Inhibition constants of 2-arylimidazobenzothiazole deriva-
tives 162a–n (values are from [108]).
Compound R1 R2 Aβ1-40 Ki (nM)
162a OMe NH2 29.8 ± 2.1
162b OMe NMe2 58.6 ± 4.7
162c F NH2 133 ± 21
162d F NHMe 38.1 ± 2.6
162e F NMe2 42.9 ± 5.7
162f Br NH2 28.8 ± 1.2
162g Br NHMe 34.5 ± 3.5
162h Br NMe2 43.4 ± 5.7
162i OMe I 10.9 ± 0.18
162j F I 41.9 ± 5.2
162k Br I 21.1 ± 0.9
162l Me I 17.7 ± 1.9
162m OMe Br 9.40 ± 0.07
162n Me Br 26.0 ± 0.9
hyde (27) to give 168 followed by radiolabeling (Scheme 13C).
The [125I]-labeled styrylquinoline 164 was prepared by using an
identical synthesis with substitution of the indole by quinoline-
6-carbaldehyde. Both 163 and 164 showed good affinity for
Aβ1-40 aggregates (Ki = 4.1 nM and 8.6 nM, respectively).
Compound 163 was able to stain Aβ plaques in in vitro brain
sections from APP/Ps1 transgenic mice and showed high uptake
and rapid clearance in normal mice (4.27% ID/g at 2 min and
0.28% ID/g at 60 min). However, compound 164 showed rela-
tively low brain uptake and slow washout by comparison.
Others
Several other less common scaffolds have been evaluated as
Aβ-imaging agents. The [125I]-labeled N-methyl-4-anilino-
phthalimide derivative 169 was prepared and evaluated as a
potential probe for Aβ plaques (Scheme 14A) [110]. This com-
pound was generated via a Cu powder-catalyzed coupling reac-
tion between N-methyl-4-aminophthalimide (170) and 1-bromo-
4-iodobenzene (171) to give 172, which was then radiolabeled.
Compound 169 showed high binding affinity to AD brain
homogenates (Kd = 0.21 nM) as well as excellent brain uptake
(5.16% ID/g at 2 min) and fast washout (0.59% ID/g at 60 min).
SAR studies with other N-methyl-4-anilinophthalimide deriva-
tives demonstrated that a hydrophobic substituent at the 4-pos-
ition of the aniline ring is important for the binding affinity of
this family of compounds.
The [125I]-labeled quinoxaline derivative 173 was also synthe-
sized and evaluated for in vivo imaging of Aβ plaques
(Scheme 14B) [111]. The quinoxaline backbone of this com-
pound was prepared from the reaction of α-bromoacetophenone
144 and 4-bromobenzene-1,2-diamine (147) in DMSO in a one-
Beilstein J. Org. Chem. 2013, 9, 1012–1044.
1038
Scheme 14: A.–C. Synthetic schemes for the preparation of radiolabeled probes with unique scaffolds.
pot tandem oxide condensation procedure. This reaction gave
the desired 2-aryl-6-substituted quinoxaline 174 as the major
product and the isomeric 2-aryl-7-substituted quinoxaline (not
shown) as a minor product. The radioiodinated probe was
prepared from 174. Compound 173 showed excellent affinity
for Aβ1-42 aggregates in vitro (Ki = 4.1 nM). In addition to
being able to specifically label plaques in brain sections from
AD patients, 173 readily crossed the BBB showing high uptake
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Scheme 15: A. Structures of the oxazine-derived fluorescence probes discussed. B. Synthetic scheme for the preparation of the oxazine analogue
183.
into the brain (6.03% ID/g at 2 min). However, with moderate
washout (1.12% ID/g at 120 min), additional refinements
will be needed to improve the pharmacokinetics of these mole-
cules.
The boron [125I]-labeled dipyrro-methane (BODIPY) analogue
175 was prepared to serve as a dual functional SPECT/fluores-
cence probe for imaging Aβ (Scheme 14C) [112]. Compound
175 was synthesized through Suzuki coupling of the starting
boronic acid 176 with 1-bromo-4-iodobenzene (171). Aldehyde
reduction of 177 followed by reaction with triphenylphosphine
gave the Wittig reagent 178 for reaction with 2-formylpyrrole
(179). The Wittig product 180 was condensed with 3,5-
dimethylpyrrole-2-carboxaldehyde (181) to form the BODIPY
backbone 182. Subsequent installation of the radiolabel gave
175. Although 175 showed decent affinity for Aβ1-42 aggre-
gates (Ki = 108 nM) and the ability to label plaques in brain
sections from transgenic mice, its in vivo use was limited by
extremely low brain uptake, which could be attributed to rapid
trapping of the compound in the liver.
Fluorescence probes
Although PET is currently the most promising approach for Aβ
plaque detection, this technique has two main limitations: (i) the
short half-life of positron-emitting nuclei (t1/2 = 20 min for
[11C] and 110 min for [18F]) and (ii) the narrow availability of
this technology that requires a local cyclotron for generating
short-lived positron-emitting radionuclides and a synthetic unit
to produce radiolabeled agents [113]. Other imaging tech-
nologies have been investigated to overcome these problems.
Different fluorescence techniques have been reported [114-
116]; however, the near-infrared fluorescence (NIRF) imaging
technique is the only one that has an in vivo application. Since
normal biological tissues reveal limited photon absorbance in
the near-infrared region, NIRF seems to be the second most
promising Aβ deposits tracer tool [117]. In the following
sections, we will briefly cover the different scaffolds that have
been explored as NIRF ligands using in vivo models.
Oxazines
The oxazine dyes 183–186 were investigated as Aβ aggregate
target-specific probes in the NIRF imaging technique
(Scheme 15A) [113]. The preparation of 183 was accomplished
t h r o u g h  r e a c t i o n  o f  4 - m e t h y l - 3 , 4 - d i h y d r o - 2 H -
benzo[b][1,4]oxazin-6-ol (187) with p-nitrobenzenediazonium
ion (188) to give the key azo intermediate 189, which afforded
the desired oxazine dye 183 upon further reaction with
4-methyl-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-ol (187)
(Scheme 15B). Compound 183 proved to give a higher fluores-
cence intensity than other derivatives such as 184–186 [113].
Using APP23 transgenic mice and compound 183, Aβ plaques
could be traced quantitatively [113].
Thiobarbitals
The thiopental dimer THK-265 (190) (maximal emission wave-
length >650 nm) was discovered as a good NIRF imaging
ligand by screening a large pool of dye candidates (Figure 6)
[117]. Compound 190 displayed high binding affinity towards
Aβ aggregates (Kd = 97 nM) [117]. Its usefulness in AD diag-
nosis was confirmed in an animal model as it provided good
discrimination between amyloid deposits in the brain and other
normal tissues [117]. Compound 190 was also used in a quanti-
tative correlation of different Aβ aggregation levels with NIRF
signals [118].
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Scheme 16: Synthetic scheme for the preparation of quinoxaline analogue 191.
Figure 6: Structure of THK-265 (190).
Quinoxalines
The use of the radiolabeled quinoxalines for imaging Aβ was
discussed in the section “Others” of this review. A quinoxaline
derivative, compound 191, was also synthesized and explored
for fluorescence imaging (Scheme 16) [119]. The synthesis of
191 began with conversion of the starting lactam 192 to the
corresponding chloride by using phosphorus oxychloride fol-
lowed by reaction with hydrazine. Condensation of the resulting
hydrazino-derivative 193 with quinoline-4-carboxaldehyde
(194) gave 191. Although 191 has not been tested in vivo yet,
this compound warrants further investigation as it has shown
the ability to selectively stain amyloid structures in brain
sections of transgenic mice, as well as the ability to cross the
BBB. In addition, the 7-fluoro substituent of compound 191
could potentially be radiolabeled for in vivo application.
Conclusion
In summary, this review covered the main scaffolds used for
radioimaging of Aβ plaques, one of the major pathological hall-
marks of AD. Highlighted were important synthetic steps for
scaffold formation and introduction of radiolabels, SAR find-
ings where appropriate, and binding affinities and brain kinetics
of each scaffold. The synthesis of each scaffold presented was
fairly straightforward using well-established reactions, and syn-
thetic complexity will likely not impede future development of
Aβ chemical probes.
Most of the scaffolds present compounds with good binding
affinity for Aβ in vitro. SARs tended to vary between scaffolds
so it is impossible, without extensive computational work, to
declare certain functionalities necessary for this class of chem-
ical probes. However, the dimethylamine structural feature
appears in a number of the compounds with high binding
affinity, and it is likely that this functionality is important for
Aβ interaction. Representative examples of this can be seen in
examining SAR trends for chalcones 18a–l, benzothiazoles
56c–t, or imidazopyridines 141a–w among others. With regards
to pharmacokinetics in vivo, results varied between scaffolds
and radiolabels. In general, [99mTc]-labeled compounds showed
poor pharmacokinetic profiles with only 125b being able to
label plaques in animal studies. A balance in lipophilicity
appeared to be particularly important in terms of pharmacoki-
netics, as imaging probes need to be lipophilic enough to easily
penetrate the BBB, but not too lipophilic to avoid nonspecific
binding in the brain.
Many of the molecules described in this review showed very
promising results for the in vivo imaging of Aβ plaques in
humans. For example, stilbenes 46a and 46b, benzothiazole
[11C]56c, and naphthalene 152 have been studied in clinical
trials with favorable results. The half-life of the radiolabel and
overall lipophilicity will continue to be two of the biggest
factors for the clinical success of these probes. Future develop-
ment and testing of these molecules will be of critical impor-
tance as the development of Aβ imaging probes will provide an
effective means of monitoring new treatments for AD. While
not the focus of this review, it should be noted that the current
treatments for AD only treat cognitive symptoms and have little
to no effect on slowing or reversing the progression of the
disease. Current research efforts aimed at developing mole-
cules that target Aβ plaques, specifically inhibition of plaque
formation and disaggregation of already formed plaques, could
lead to new therapeutics capable of reversing the progression of
AD. Probes such as those described herein will play an impor-
tant role in evaluating the effectiveness of such drugs. Add-
itionally, the development of Aβ imaging probes will likely lead
to better and earlier diagnosis of AD, which in turn will allow
future treatments to be more effective.
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